PostEra has expanded its partnership with Pfizer to include a new ADC collaboration and extend their $260M AI Lab agreement, building on their previous Generative Chemistry partnership

The teams will use PostEra’s AI platform, Proton, to optimize small molecule therapeutics and ADC payloads

PostEra will receive $12M upfront and be eligible for milestone payments and royalties on approved products

After three years of collaboration on small molecule programs, PostEra and Pfizer will expand their partnership to include additional targets, with PostEra receiving further payments and royalties

This third partnership with Pfizer highlights Proton’s impact on drug discovery